Medical Innovation Exchange

AbbVie's Roche-rivaling blood cancer bispecific gets FDA priority review, triggering Genmab payday

https://www.fiercebiotech.com/biotech/abbvies-roche-rivaling-blood-cancer-bispecific-gets-fda-priority-review-triggering-payday

Leave a Comment

Your email address will not be published. Required fields are marked *

Leave the field below empty!